SCHEMBL6720867

SCHEMBL6720867

CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(S(=O)(=O)c4ccc(NC(C)=O)cc4)CC3)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 1.00
ALDH1A1 P00352 8/20 1.00
HPGD P15428 6/20 1.00
HTT P42858 6/20 1.00
TDP1 Q9NUW8 4/20 1.00
POLB P06746 2/20 1.00
GAA P10253 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
LMNA P02545 4/20 0.85
MAPT P10636 2/20 0.85
TP53 P04637 1/20 0.85
KMT2A Q03164 5/20 0.66
MEN1 O00255 4/20 0.66
HSD17B10 Q99714 3/20 0.66
TSHR P16473 2/20 0.66
USP2 O75604 1/20 0.66
NPC1 O15118 1/20 0.66
DRD3 P35462 1/20 0.63
ATM Q13315 1/20 0.63
BRD4 O60885 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12325899 0.95 KDM4E (0.91) KDM4EALDH1A1HPGDHTTTDP1
SCHEMBL9407621 0.88 ALDH1A1 (0.84) KDM4EALDH1A1HPGDHTTTDP1
SCHEMBL6308402 0.87 ALDH1A1 (0.81) KDM4EALDH1A1HPGDHTTTDP1
SCHEMBL13856427 0.86 ALDH1A1 (0.76) KDM4EALDH1A1HPGDHTTTDP1
SCHEMBL4719318 0.86 ALDH1A1 (0.80) KDM4EALDH1A1HPGDHTTTDP1
SCHEMBL9223089 0.85 KDM4E (0.74) KDM4EALDH1A1HPGDHTTTDP1
SCHEMBL6298452 0.82 ALDH1A1 (0.80) KDM4EALDH1A1HPGDHTTTDP1
SCHEMBL8706968 0.82 KDM4E (0.69) KDM4EALDH1A1HPGDHTTTDP1
SCHEMBL12325898 0.81 ALDH1A1 (0.68) KDM4EALDH1A1HPGDHTTTDP1
Pefloxacin SCHEMBL29594648 0.80 KDM4E (1.00) KDM4EALDH1A1HPGDHTTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436031-B2 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2013-05-07 US disclosed
US-8183236-B2 Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-05-22 US disclosed
US-8183236-B2 Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-05-22 US disclosed
US-7928113-B2 Integrin-binding small molecules UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2011-04-19 US disclosed
US-7928113-B2 Integrin-binding small molecules UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2011-04-19 US disclosed
EP-2298308-A2 Integrin-binding small molecules University Of Southern California (US) 2011-03-23 EP disclosed
US-20090131401-A1 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2009-05-21 US disclosed
US-20090131401-A1 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2009-05-21 US disclosed
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-04-02 US disclosed
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-04-02 US disclosed
US-7405235-B2 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-7405235-B2 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-20070155750-A1 INTEGRIN-BINDING SMALL MOLECULES USC STEVENS-UNIVERSITY OF SOUTHERN CALIFORNIA 2007-07-05 US disclosed
US-20070155750-A1 INTEGRIN-BINDING SMALL MOLECULES USC STEVENS-UNIVERSITY OF SOUTHERN CALIFORNIA 2007-07-05 US disclosed
WO-2007059195-A1 INTEGRIN-BINDING SMALL MOLECULES UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131401-A1 Transcription factor modulating compounds and methods of use thereof JUN, CREBBP, TFEB KDM4E 360/4885ALDH1A1 3948/4885HPGD 2406/4885
US-20070155750-A1 INTEGRIN-BINDING SMALL MOLECULES ITGB3, ITGB5, ITGA2B KDM4E 3949/4885ALDH1A1 2723/4885HPGD 3564/4885
US-20090088420-A1 COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS TYMP, IMPDH1, SAMHD1 KDM4E 1795/4885ALDH1A1 265/4885HPGD 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.